The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
Official Title: Clinical Characteristics, Outcomes and Quality of Life in Patients With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab After Prior Chemotherapy as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
Study ID: NCT04936399
Brief Summary: This purpose of this observational study is to review medical chart and patient survey data collection within an early access to medicines scheme (EAMS) program. Participant who are eligible, provide consent and enroll into the squamous cell oesophageal cancer EAMS to receive Nivolumab will be included in this study.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Local Institution - 0006, Truro, Cornwall, United Kingdom
Local Institution, London, Greater London, United Kingdom
Local Institution, Maidstone, Kent, United Kingdom
Local Institution, Glasgow, Lanarkshire, United Kingdom
Local Institution, Grimsby, Lincolnshire, United Kingdom
Local Institution, Edinburgh, Scotland, United Kingdom
Local Institution, Birmingham, West Midlands, United Kingdom
Local Institution, Leeds, West Yorkshire, United Kingdom
Local Institution, Basingstoke, , United Kingdom
Local Institution, Bebington, , United Kingdom
Local Institution, Belfast, , United Kingdom
Local Institution, Birmingham, , United Kingdom
Local Institution, Blackburn, , United Kingdom
Local Institution - 0037, Bristol, , United Kingdom
Local Institution, Cambridge, , United Kingdom
Local Institution, Cardiff, , United Kingdom
Local Institution, Cottingham, , United Kingdom
Local Institution, Coventry, , United Kingdom
Local Institution, Derby, , United Kingdom
Local Institution, Devon, , United Kingdom
Local Institution, Dundee, , United Kingdom
Local Institution, Headington, , United Kingdom
Local Institution, Lancaster, , United Kingdom
Local Institution, London, , United Kingdom
Local Institution, London, , United Kingdom
Local Institution, London, , United Kingdom
Local Institution, Manchester, , United Kingdom
Local Institution, Melrose, , United Kingdom
Local Institution, Northwood, , United Kingdom
Local Institution, Nottingham, , United Kingdom
Local Institution, Pembrokeshire, , United Kingdom
Local Institution, Preston, , United Kingdom
Local Institution, Surrey, , United Kingdom
Local Institution, Surrey, , United Kingdom
Local Institution, Taunton, , United Kingdom
Local Institution, Walsall, , United Kingdom
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR